Recently, using immunohistochemical methods, we surprisingly found that endoplasmic reticulum glucose-6-phosphatase is present in human embryonic and fetal red blood cells (RBCs) but not in adult RBCs. The fact that an endoplasmic reticulum enzyme, whose major site of expression in adults is the liver, is present in human embryonic and fetal RBCs, particularly nucleated cells, indicated that it would be sensible to determine whether these cells also contain other endoplasmic reticulum enzyme systems normally found in adult liver. Therefore, we have studied the expression of other endoplasmic reticulum proteins and found that human embryonic and fetal RBC precursors contain other protein components of the glucose-6-phosphatase system, ie, the phosphate and glucose transport proteins as well as other enzymes (eg, uridine diphosphate-glucuronosyltransferases, catalyzes the terminal step of glycogenolysis and gluconeogenesis and is expressed predominantly in liver, in which it plays a major role in the regulation of blood glucose levels.' Recently, we surprisingly found that glucose-6-phosphatase was also present in human embryonic and fetal red blood cells (RBCs),' although it had previously been shown to be absent in adult human RBCS.' The hepatic microsomal glucose-6-phosphatase system has been extensively characterized in the last few years: and, for normal glucose-6-phosphatase activity in vivo, at least six different proteins are needed.s The catalytic subunit of the glucose-6-phosphatase enzyme is situated with its active site inside the lumen of the endoplasmic reticulum, and it is associated with a Ca2+ binding p r~t e i n .~ Three transport systems termed T1, T2, and T3 are also needed to respectively transport the substrate glucose-6-phosphate6 and the products phosphate and glucose across the liver-endoplasmic reticulum To verify and expand our original observation of the immunological presence of glucose-6-phosphatase enzyme and with the recent availability of specific cDNA probes for the liver enzyme, we now show the presence of glucose-6-phosphatase enzyme mRNA in human fetal RBCs. For human em- 7, 1995; accepted September 24, 1995. Supported by grants from the Scottish Home and Health Department (to A.B. and R.H.), the Wellcome Trust (to B.B. and R.H.), and the National Kidney Research Fund (to A.B. and R.H.) and by equipment grants from the Royal Socieo (to A.B.) and Tenovus (Scvtland; to A.B. and R.H.) 
cytochrome P450 isozymes, nicotinamide adenine dinucleotide phosphate cytochrome P450 oxidoreductase, and prostaglandin H synthase). In addition, we also found the predominantly cytosolic markers 15-hydroxyprostaglandin dehydrogenase, prostaglandins PGE2 and 13.14-dihydro-15-keto-PGE,. The expression of key enzymes that control glucose production, detoxification of endobiotics and xenobiotics, and the regulation of prostaglandin levels in embryonic and early fetal RBCs means that these cells may have an important role in protecting the developing conceptus before it establishes an efficient circulation and before all tissues fully express their normal complement of these enzymes. 0 1996 by The American Society of Hematology.
bryonic and fetal RBCs to produce glucose, not only the intraluminal endoplasmic reticulum glucose-6-phosphatase enzyme but also the associated endoplasmic reticulum transport proteins are required. Therefore, we have used specific antibodies'*'" to study the expression of T2 and T3 in human embryonic and fetal RBCs. The fact that an endoplasmic reticulum system (glucose-6-phosphatase), whose major site of expression in adults is liver, is present in human embryonic and fetal RBCs, particularly nucleated cells, raises the possibility that these cells might also contain other endoplasmic reticulum enzyme systems normally considered to be predominantly present in liver. Thus, we have studied the expression of other endoplasmic reticulum proteins uridine diphosphate-glucuronosyltransferases (UGTs), cytochrome P450 isozymes, nicotinamide adenine dinucleotide phosphate (NADPH) cytochrome P450 oxidoreductase, and prostaglandin H synthase (PGHS), as well as the relevant and predominantly cytosolic markers 15-hydroxyprostaglandin dehydrogenase, prostaglandin E, (PGE,) and 13,14-dihydro-1.5-keto-PGE2 (PGEM).
MATERIALS AND METHODS

Tissue Samples
Human embryonic tissue was obtained within 1 hour after termination of pregnancies of a duration of less than 56 days amenorrhea using Mifepristone (Roussel, Uxbridge, UK) and Gemeprost vaginal pessaries (May and Baker, Dagenham, UK). Stages of embryonic development and the approximate postovulatory days of age were performed according to established morphological criteria." Fetal tissue was obtained within 6 hours after termination of pregnancy using Gemeprost vaginal pessaries. Blood samples (up to 1 mL) were obtained by cardiac puncture from fetuses 13 to 20 weeks gestation. Fetal developmental age was carefully estimated based on size, including crown-heel, crown-rump, and heel-toe measurements"; menstrual history; and ultrasound dating of pregnancy. Normality of fetuses was confirmed by autopsy. Adult tissue was obtained at routine postmortem within 12 hours of certification of death. The study was approved by the PaediatriclReproductive Medicine Ethics of Medical Research Subcommittee of Lothian Health Board (Scotland) and the Ethics Committee of Tayside Health Board (Scotland).
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weeks' gestation); and liver from 2 adults were fixed in 10% buffered formalin for 5 days and processed routinely to paraffin wax.
Antibodies
Antibodies directed against purified rat liver testosterone/4-nitrophenol UGT were raised in Suffolk Cross Blackface sheep by a combination of intradermal and subcutaneous injection. IgG was prepared from the antiserum by a combination of ammonium sulphate precipitation and diethyl aminoethyl-cellulose chromatography." This sheep antirat liver testosterone/4-nitrophenol UGT antibody preparation (RAL 1) inhibited UGT activity towards bilirubin, testosterone, l-naphthol, androsterone, estrone, and morphinela; and immunoblotting confirmed a broad spectrum of cross-reactivity to multiple isoforms in rat and human adult and fetal liver micros o m e~. '~.~~ Monospecific polyclonal antisera to the catalytic subunit of the microsomal glucose-6-phosphate system, T2, and T3 were each raised in Cheviot sheep by 3 subcutaneous injections of 80 pg of purified protein and Freund's complete adjuvant as de~cribed.~."'.~~ Preimmune serum was obtained from each sheep before injection with antigen. The glucose-6-phosphatase enzyme, T2, and T3 used as antigens were all isolated from starved Wistar rat hepatic microsomes. Antisera were further purified by (NH&S04 fractionation and affinity purification using protein G columns, and the resultant antibody preparations were used at protein concentrations described below. The antibody preparations, although raised against rat liver proteins, have been shown many times to each cross-react well with the respective human protein~~,~.~'.l* as judged by immunoblot analysis after sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Antisera were raised in rabbits to methyl-moximated PGEM (PGEM-MOX) coupled to bovine serum albumin." In radioimmunoassay, the PGEM-MOX antiserum has only a 0.05% cross-reactivity with PG&. Cross-reactions of PGEM-MOX antiserum to other methyl-moximated PGs were less than 0.02%, except for 15-keto-PGE2 (12%) and 15-keto-PGEh (0.9%). The percentage cross-reactivities of PGEM-MOX antiserum to other PGs were less than 0.02%. except for 6,15-diketo-13,14-dihydro-PGEb (0.35%); 13,14-dihydro-PGEz, (2%); and 15-keto-PGFb (4%).Iy Cross-reactivity of Gemeprost to PGEM-MOX antiserum was less than 0.03% and to PGFM-MOX antiserum, 0.03%.21 Antibody specificity of PGEM-MOX antiserum for immunohistochemistry was shown by selective absorption of immunostaining by PGEM-MOX." Anti-PGHS-l, a polyclonal goat IgG fraction with cross-reactivity to PGHS-l from a number of mammalian species but negligible reactivity to PGHS-2, and a monoclonal 15-hydroxyprostaglandin dehydrogenase antibody were purchased from Oxford Biomedical Research, Inc (Oxford, MI).
PG& was conjugated to keyhole limpet hemocyanin and injected intradermally into sheep. The resultant PGE,-antiserum was a kind gift from Dr T. Parkinson (Bristol University, Bristol, UK). On radioimmunoassay, PG&-antiserum was highly group-selective, with minimal cross-reactivity between the F and E series of PGs." Cross-reactivity of Gemeprost to PGE,-antiserum was less than
Antisera specificity for immunohistochemistry was tested by selectivity of absorption of immunostaining by PGE, in human fetal lung. 20 Antibodies to purified cytochrome P450s were isolated as described previously.2z These antibodies have previously been extensively used in immunoblotting studies with mouse microsomal samp l e~.~~. "
In addition, the isozyme specificities of the antisera have been shown by immunoblot analysis with expressed human recombinant cytochrome P450 protein^.'^ NADPH-cytochrome P450 oxidoreductase was purified," and antibodies raised in rabbits were shown previously to cross-react with the human enzyme on sodium dodecyl sulfate-polyacrylamide gel electrophoresis.26
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue was cut at 3-pm sections. The first section was stained with hematoxylin and eosin to confirm normality and developmental characteristics. Immunohistochemistry was performed on sequential sections with antibody preparations diluted to: glucose-6-phosphatase (0.5 mg/mL), T2 (0.3 mg/ mL), and T3 (0.1 mg/mL) as described in human liver, brain, kidney, and adrenal2""; anti-rat liver testosterone/4-nitrophenol UGT (RAL 1) (2.2 mg/mL) as described in human kidney"; PGHS-1 (0.15 mg/mL); 15-hydroxyprostaglandin dehydrogenase (0.02 mg/mL) as described in decidua and PG& (0.01 mg/mL) and PGEM-MOX (0.2 mg/mL) as described in human fetal lung, decidua, and chorionm."; and cytochrome P450 CYP2B1 (0.05 mg/mL), cytochrome P450 CYP4Al (0.1 mg/mL.), and NADPH cytochrome P450 oxidoreductase (0.1 mg/mL). On further sections, negative controls were made by replacing each of the individual primary antibody preparations with nonimmune serum. A standard peroxidase-antiperoxidase technique was used incorporating 3,3-diaminobenzidine as the developing agent.33 Sections were lightly counterstained with hematoxylin, dehydrated through graded alcohols, and cleared in xylene before coverslipping in synthetic resin.
Cell Counting
Tissue sections through the heart or the major mediastinal or pulmonary vessels with discrete intraluminal blood cells were selected, and, with the aid of a Zeiss Axioskop light microscope fitted with an eye-piece grid, more than 1, OOO RBCs were counted and reviewed per embryo/fetus. To avoid cell overlap, at least a 21-pm gap between tissue sections was allowed when multiple sections were counted. Individual RBCs were designated first on the basis of size as part of the definitive or normoblastic series or of the primitive or megaloblastic series of erythropoeisis; then on the presence or absence of a nucleus or nuclear remnants; and finally on whether they were positive or negative for immunoreactivity.
Data and Graphics
CA-Cricket Graph 111 (Computer Associates, Plaza Islandia, NY) was used for data storage and graphics. Exponential curves, with the general equation y = IOmx+b, were fitted using the linear leastsquares regression method to determine the best curve fit for the data.
RNA Isolation
Total RNA was isolated from postmortem adult human liver and human fetal blood using a modification of the short-acid guanidium thiocyanate-phenolkhloroform extraction method of Chomczynski and S a~c h i '~ using the Micro-Scale Total RNA Separator Kit (Clontech Lab, Palo Alto, CA). The amount of fetal blood used initially ranged from 20 pL to 500 pL, depending on the amount available from any particular sample. Messenger RNA (&A) was isolated from total fetal blood using a QuickPrep Micro mRNA Purification Kit (Pharmacia, Uppsala, Sweden).
Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR)
RT-PCR was performed on total RNA by incubating approximately 0.5 pg of total RNA or 0.1 pg mRNA with an antisensespecific primer 5'GCCTTACAAAGACTTC'ITGTG, corresponding to nucleotides 1136 to 1157 of the human glucose-6-phosphatase mRNA sequence, for the RT stage and a specific sense primer 5' TCTGCTGACATCTTCCT, corresponding to nucleotides 43 to 60 of the human glucose-6-phosphatase mRNA seq~ence,'~ for PCR.
RT-PCR products were separated on a 0.8% agarose gel and then transferred to a nylon membrane (Hybond N+; Amersham, Bucking- and corresponding to nucleotides 704 to 1 156 of the human glucose-6-phosphatase mRNA seq~ence'~ was hybridized to the filter overnight at 68°C. The filter was washed twice at 55°C with 0.2X SSC and 0.1% SDS and was autoradiographed overnight.
RESULTS
RBCs
Glucose-6-phosphatase system. Immunohistochemistry using antibodies against the glucose-6-phosphatase transport proteins, T2, and T3 shows a similar developmental pattern to that previously described for glucose-6-phosphatase enzyme' in both embryonic and fetal RBCs (see Figs 1A and  B) . Immunopositivity is predominantly in nucleated primitive megaloblastic cells, with a few nonnucleated megaloblastic cells also being positive. Later in the transition of switch-over in late embryonic-early fetal life, T2 and T3 immunopositive cells are definitive normoblastic in type, with a variable contribution from nucleated and nonnucleated cells. Thereafter, the number of immunopositive cells in the definitive normoblastic series decreases to the point that, after 12 weeks' gestation, it is a very small percentage. RNA was isolated from human fetal blood, 13 to 18 weeks' gestation. RT-PCR, using primers and cDNA probes specific for the liver glucose-6-phosphatase enzyme, confirms the presence of glucose-6-phosphatase mRNA in four of the five samples tested (Fig 2, lanes 3 through 6 ) . That one sample was negative (Fig 2, lane 2) , is not surprising because, for a variety of technical and ethical reasons, delays in obtaining blood are inevitable and RNA is known to degrade rapidly. Although lane 7 of Fig 2 appears to give a negative result, more prolonged autoradiography resulted in the visualization of bands (Fig 2, lane 7 UGT. In embryos, the majority of the UGT-immunopositive cells are in the primitive megaloblastic cell series ( Fig  IC and Fig 3) , with nucleated cells predominating (mean, 38%; range, 25% to 45%). In some embryos, up to 24% of immunoreactive cells are nonnucleated megaloblastic cell types (mean, 22%; range, 19% to 24%). In late embryonic and into early fetal life (8 to 12 weeks' gestation), there is " 1 +l a divergence between the number of UGT-immunopositive cells and the total number of cells in the primitive megaloblastic cell series (Fig 3) . At this time, microscopy shows a mixed population of cells of the megaloblastic and normoblastic series (Fig ID) , and, at which point. up to 54% of the total immunopositive cells are definitively normoblastic in type (Fig 3) , with a variable percentage of contribution from both nucleated and non-nucleated cells. Thereafter, the number of immunopositive cells in the definitive normoblastic series decreases to the point that, after 12 weeks' gestation, it is less than 5% of the total (Fig IE and Fig 3) .
PG system. The percentage distribution of PGHS-immunopositive RBCs with development is similar to that of UGT and glucose-6-phosphatase.' In early embryos, PGHS immunoreactivity is predominantly present in nucleated megaloblastic cells. In late embryos-early fetuses, the number of megaloblastic cells decreases, with a higher percentage contribution of immunopositive cells from the normoblastic series (Fig IF) . Thereafter, the number of immunopositive normoblastic cells decreases to the point that, after 12 weeks' gestation, it is less than 5%. A similar cell distribution and immunoreactivity pattern with ontogeny is also observed using antibodies against PGE,, PGEM, and 15-hydroxyprostaglandin dehydrogenase. RT-PCR using primers specific for PGHS-I, using the same samples as in Fig 2, showed the presence of PGHS-I mRNA in fetal blood (data not shown).
Cytochrome P450 system. The distribution of immunopositive RBCs with development, using antibodies against cytochrome P450CYP2B l , cytochrome P450CYP4A I , and NADPH cytochrome P450 oxidoreductase, is similar to that of UGT and glucose-6-phosphatase.
Liver, Spleen, and Kidney
The parenchymal cells of the liver are derived from the hepatic diverticulum of the embryonic foregut, and, in the earliest human embryos available to us (32 postovulatory days [stage 14]), columnar cords of epithelium are obvious and extend into the surrounding mesodermal stroma ( Fig  4A) . Those developing hepatocytes are weakly UGT-immunopositive, whereas the predominantly megaloblastic RBCs in the liver sinusoids are more intensely stained (Fig 4A) . UGT immunostaining increases to moderate intensity in hepatocytes during fetal life (Figs 4B and C). Hematopoietic cells are more intensely UGT-immunoreactive than hepatocytes (Fig 4B and C) : B, F, G, H, and l. ~230; A, ~4 6 0 ; and C, D, and E, ~1,140.)
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embryonic and fetal liver, with circulating blood cells being largely immunonegative (Fig 4B) . UGT immunostaining in adult liver hepatocytes is intense, and hematopoietic cells are absent (Fig 4D) .
In fetal spleen, foci of erythropoiesis are not only less numerous but also contain fewer cells than in liver of similar gestation (compare Figs 4C and E) . UGT-immunoreactive hematopoietic cells are present, with occasional nonnucleated immunopositive RBCs and many immunonegative RBCs (Fig 4E) .
In the earliest embryo available (32 postovulatory days), the most primitive condensations of nephritic tissue of the mesonephric kidney are UGT-immunonegative (Fig 4F) . With further development of the mesonephric kidney (still present up to 9 to 10 weeks' gestation), glomeruli are UGTimmunonegative and tubules and the mesonephric duct are weakly immunopositive (Fig 4G) , whereas embryonic blood cells are intensely immunoreactive (Fig 4G) .
The ureteric bud of the developing metanephric kidney elongates to form the ureter and renal pelvis in 5-to 14-week-old embryos and fetuses and then sequentially divides into calyces and collecting ducts. UGT immunostaining has a distinct caudal to rostral pattern of reactivity in the ureteric bud derivatives of the early metanephric kidney, decreasing from the pelvis through the length of the developing collecting ducts so that the most rostral cells at the growing ends of the ducts are UGT-immunonegative (Fig 4H) . This gradient of reactivity is still obvious in the collecting ducts and tubules until the end of the period of nephrogenesis at around 34 to 36 weeks' gestation; however, with the development of an early transitional epithelium between 10 and 20 weeks' gestation, the ureter, pelvis, and calyces become UGT-immunonegative (data not shown).
During the period of active nephrogenesis, from 8 to 34 weeks' gestation, the subcapsular cells and cellular masses that constitute the developing glomerulo-tubular complexes are UGT-immunonegative (Fig 4H) . With the formation of renal vesicles and S-shaped bodies, weak focal positivity is present in some cells, and, with further development, the parietal layer of Bowman's capsule and the developing nephrons become intensely UGT-immunopositive (Fig 41) . Glomeruli remain immunonegative. All segments (proximal, loop of Henle, and distal tubule) retain UGT immunoreactivity as the nephrons elongate and differentiate from around 12 weeks' gestation, with the most intensive staining occurring in proximal tubules, where this is uniform in cellular distribution (Fig 41) . This distribution of immunoreactivity is retained into infancy and adulthood.
We have previously shown a very similar distribution of glucose-6-phosphatase proteins in liver and and in the PG system (data not shown).
DISCUSSION
Blood formation has been detected as early as 14 postovulatory days, arising from primitive blood cells or hematocytoblasts within the human embryonic yolk
In the developing embryo, two distinct generations of erythrocytes can be observed as a result of either primitive megaloblastic erythropoiesis or definitive normoblastic erythrop~iesis.~~ The onset of definitive normoblastic erythropoiesis is delayed until about the sixth gestational week; however, by the 10th week, it accounts for more than 90% of the circulating erythrocyte^.^^ At about the 35th day of gestation, erythropoeisis begins in the liver, and, between the 12th and 20th week, erythroid precursors represent approximately 50% of the total nucleated cells of this The human liver is the major site of erythropoiesis until around 24 to 30 weeks' gestation, and, even at term (40 weeks' gestation), RBC precursors can still be detected,39 although the major site of hemopoiesis has moved to bone marrow. In contrast to primitive megaloblastic erythropoiesis, maturation is primarily extravascular in normoblastic erythropoiesis, which is the likely explanation for the difference in the ratio of nucleated to non-nucleated cells and, consequently, in the number of blood cells immunopositive for the endoplasmic reticulum proteins in the vascular compartment for each of these forms of erythropoiesis. Because endoplasmic reticulum proteins normally associated with hepatocytes are also present in erythroid precursors in the hepatic sinusoidal spaces of the early embryo and the hepatic erythropoietic tissue of the late embryo-early fetus, ontogenic studies of embryonic-fetal liver expression of enzymes, based solely on conventional assays, may have to be reassessed:' as will the diagnosis of genetic deficiencies of hepatic endoplasmic reticulum proteins using fetal hepatic biopsy samples (eg, type-I glycogen storage disease [glucose-6-phosphatase defi~iency]).~~
The process of erythropoiesis is directed towards producing a mature cell devoid of organelles but packed with hemoglobin. The first discernable erythrocyte precursor, after the unipotent stem cell, is the proerythroblast, which progresses through a series of normoblastic stages to the reticulocyte and finally to the mature erythrocyte. In the early normoblast stages, organelles begin to be extruded, followed by the nuclear remnant in the late normoblast phase.39 Clearly, new protein synthesis is dependent on both an intact and functioning nucleus as well as an endoplasmic reticulum-ribosome complex. After the extrusion of the nucleus or endoplasmic reticulum, proteins remaining within the maturing cell will decay with variable half-lives. The glucose-6-phosphatase system (glucose-6-phosphatase enzyme, T2 and T3), PGHS, cytochrome P450, NADPH cytochrome P450 oxidoreductase, and UGT enzymes are endoplasmic reticulum proteins; therefore, because this organelle is extruded with maturation, immunopositivity to these proteins is variable in intensity and is predominantly confined to nucleated precursors, with the majority of mature non-nucleated cells being immunonegative. Cytochrome P450, NADPH cytochrome P450 oxidoreductase, and UGT are key enzymes in the biotransformation and elimination of a wide variety of lipophilic endogenous compounds, drugs, toxins, carcinogens, teratogens, and other x e n o b i o t i~s .~~.~ Liver and kidney are major sites of expression of these enzymes in the adult human, but little is known about their expression in early human development.
The parenchymal cells of the liver are derived from the hepatic diverticulum of the embryonic foregut; however, compared with the onset of yolk sac erythropoiesis, this process is delayed to as late as 26 postovulatory days (stage 12)." In addition, hepatocytes in the embryo and early fetus are less immunoreactive for endoplasmic reticulum proteins For personal use only. on October 31, 2017. by guest www.bloodjournal.org From than either circulating megaloblastic blood cells or the precursors of normoblastic erythropoiesis in fetal liver. Studies of UGT enzyme activities in developing human liver have shown that only 5-hydroxytryptamine, l-naphth~l?~ and morphine& are glucuronidated to any significant extent by mid-trimester fetal liver, and activities to a further range of substrates are delayed until after birth?734* UGT enzyme studies in mature kidney have shown that activity is predominantly localized to the c~r t e x~~~' "~' ' and this is consistent with the immunohistochemical distribution of the proximal tubules having the most intense UGT immun~reactivity,'~~'~~'~ with lesser degrees of reactivity in other tubular components and collecting d u~t s . '~ In the mesonephric kidney, a patent mesonephric duct and nephric tubules are present in human embryos from stage 12 (26 post-ovulatory days)," but our studies have shown that UGT immunoreactivity is only present (albeit weakly) for the first time between 32 and 37 postovulatory days, when circulating RBCs are already intensely immunoreactive. Mesonephric kidney in the chick embryo has been shown to glucuronidate 2-aminophenol?' and the mesonephric duct and tubules are UGT-immunopositive in humans, which may in part compensate for the lack of proximal tubular and concomitant UGT development in the metanephric kidney. In a similar manner, the derivatives of the ureteric bud (ie, the ureter, pelvis, and calyces) are transiently UGT-immunopositive in the early metanephric kidney, and this may also compensate for proximal tubular glucuronidation insufficiency at this stage of development. In addition, development of the metanephric kidney proximal tubules and, hence, UGT immunoreactivity is limited for the remainder of embryonic life (56 postovulatory days) and early fetal life, suggesting that glucuronidation may remain low at a time when the developing conceptus is most vulnerable to the effects of teratogens. It is important that the early embryo is protected from the detrimental effects of potential transplacental teratogens a n d or carcinogens as well as endobiotics. Therefore, it seems logical that the circulating erythropoietic system may play a role in endobiotic and xenobiotic detoxification in early human development before the liver and kidney fully express their normal complement of these enzymes.
The major sites of expression of the glucose-6-phosphatase system in adult humans are the liver and kidney." We have previously used immunohistochemical methods to detect the presence of glucose-6-phosphatase enzyme, T2, and T3 in developing human tissue, which was not previously thought to express this system, and subsequently showed the presence of specific glucose-6-phosphatase enzyme activity and microsomal glucose-6-phosphate, phosphate, and glucose tran~port.~' The role of glucose-6-phosphatase in tissues that normally are not net producers of blood glucose (eg, brain astrocyte^)'^ is not clear, although local intercell glucose production seems likely; for example, astrocytes may produce glucose for adjacent neurons. The human embryonic heart only begins to beat after 28 postovulatory days,s6 and, before the establishment of an effective cardiac output, the circulation is likely to be sluggish at a time of major metabolic need in rapidly developing tissues. The presence of circulating glucose-producing RBCs might act to alleviate hypoglycemia in areas of high metabolic demand andor temporary poor circulation.
PGs have important roles in the regulation of physiological processes in the developing fetus including control of the pulmonary vasculature, ion and water secretion, inflammation, surfactant secretion, and cilia1 m~vement.'~ PGs are established autocoids and, in developing tissues, act as transmembrane signals for a variety of hormones and growth factors modulating differentiati~n~"~' as well as cell proliferation in a variety of cell types. 6' PGs are synthesized from arachidonic acid, a reaction catalyzed by the cyclo-oxygenase and peroxidase activity of PGHS with the formation of the common intermediate PGH?, which is then converted to a number of biologically active products including PGE2, PGFh, thromboxane A,, and prosta~yclin.'~ PGE2 and PGF,, are inactivated by the enzyme 1.5-hydroxyprostaglandin dehydrogenase leading to the formation of 15-keto-PGE2 or 15-keto-PGF,, and then these are converted to PGEM and PGFM through the action of a 13,14-red~ctase.~ The presence of the enzymes PGHS and 1 S-hydroxyprostaglandin dehydrogenase and their products PGE, and PGEM indicates that some embryonic and fetal RBCs have the ability to synthesize and degrade PGs. The role of PGs in human embryos and early fetuses has not been delineated. The presence of PG metabolizing enzymes in circulating cells early in human development may provide a means of synchronous delivery or removal of signals to a variety of cell types that may not possess all the enzymes in these pathways.
The ability to control glucose production, to detoxify endobiotics and xenobiotics, and to regulate PG levels are essential for homeostasis and normal development in the human fetus. The expression of key enzymes in these processes in embryonic and early fetal RBCs, in contrast to adult RBCs, may protect the developing conceptus before it establishes an efficient circulation.
Genetic deficiencies of some of the endoplasmic reticulum proteins described in this report result in metabolic disorders of such severity that affected families often request prenatal diagnosis. Type-Ia glycogen storage disease (von Gierkes disease) is a result of the liver glucose-6-phosphatase enzyme; type-Ib glycogen storage disease is a deficiency of endoplasmic reticulum glucose-6-phosphate transport T1; type-Ic glycogen storage diseases are deficiencies of endoplasmic reticulum phosphate andor pyrophosphate transport; and type-Id glycogen storage disease is a deficiency of endoplasmic reticulum glucose transport.' Crigler-Najjar syndrome is a result of the deficiency bilirubin uridine diphosphate-glu~uronosyltransferase.~~ Although some forms of these deficiencies can be unequivocally diagnosed using DNA analysis, others cannot. The discovery of these proteins in embryonic and early fetal blood raises the exciting possibility of diagnosis of these deficiencies early in pregnancy by using blood cells from the first trimester conceptus that are present in and can be isolated from maternal blood.
